Sino Biopharmaceutical Receives NMPA Approval for Pan-KRAS Inhibitor TQB3205 Clinical Trial
核心洞察
Sino Biopharmaceutical's subsidiary CTTQ (搜索) received NMPA approval to begin clinical trials for TQB3205 (搜索), a pan-KRAS (搜索) inhibitor targeting advanced malignant tumors (搜索).
TQB3205 (搜索) addresses a significant unmet need by targeting multiple KRAS (搜索) mutation subtypes beyond G12C, potentially treating broader patient populations with KRAS-mutant cancers.
KRAS (搜索) mutations are present in approximately 30% of all cancers worldwide, with high prevalence in pancreatic cancer (搜索) (90%), colorectal cancer (搜索) (30%-50%), and non-small cell lung cancer (搜索) (15%-20%).
Sino Biopharmaceutical Limited announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group (搜索) Co. Ltd. (CTTQ (搜索)), has received clinical trial approval from China's National Medical Products Administration (NMPA) for TQB3205 (搜索), a national Category 1 innovative drug targeting advanced malignant tumors (搜索). The oral pan-KRAS (搜索) inhibitor represents a significant advancement in addressing unmet needs in oncology treatment.
Novel Mechanism Targets Multiple KRAS Mutations
TQB3205 (搜索) operates through a distinctive mechanism of action that sets it apart from currently available therapies. The drug binds multiple KRAS (搜索)-mutant proteins with high affinity and blocks RAS activation by inhibiting SOS1 (搜索)-mediated nucleotide exchange in KRAS. This process suppresses phosphorylation of downstream ERK (搜索), effectively inhibiting proliferation of various KRAS-mutant tumor cells.
The therapeutic approach addresses a critical gap in current treatment options. While approved KRAS (搜索) inhibitors globally only target the G12C mutation subtype, TQB3205 (搜索) is designed to target multiple KRAS mutation subtypes, including G12V, G12D, and G13D variants.
Addressing Significant Unmet Medical Need
KRAS (搜索) mutations represent one of the most prevalent oncogenic drivers across multiple cancer types. According to the company's data, KRAS mutations are present in approximately 30% of all cancer cases worldwide, with KRAS accounting for 85% of RAS mutations. The mutations show particularly high prevalence in several aggressive cancer types:
- Pancreatic cancer: 90% prevalence
- Colorectal cancer: 30%-50% prevalence
- Non-small cell lung cancer: 15%-20% prevalence
The limited therapeutic options for patients with non-G12C KRAS (搜索) mutations have created a substantial treatment gap that TQB3205 (搜索) aims to address.
Building on Recent Oncology Success
The clinical trial approval for TQB3205 (搜索) follows Sino Biopharmaceutical's recent achievement in the KRAS (搜索) inhibitor space. In November 2024, the company's KRAS G12C inhibitor, garsorasib (trade name: Anfangning (搜索)), received NMPA marketing approval, demonstrating the company's growing expertise in targeting KRAS-driven cancers.
This dual approach positions Sino Biopharmaceutical to address both G12C and non-G12C KRAS (搜索) mutations, potentially covering a broader spectrum of patients with KRAS-mutant advanced malignant tumors (搜索).
Strategic Development Commitment
The company has committed to accelerating clinical development of TQB3205 (搜索), aiming to overcome existing treatment limitations and provide novel therapeutic options for patients with KRAS (搜索)-mutant advanced malignant tumors (搜索). The strategic focus on rapid clinical progression signals the company's confidence in the drug's potential and commitment to addressing this significant unmet medical need.
The clinical trial approval represents a strategically significant milestone for Sino Biopharmaceutical as it enters a highly competitive area of oncology drug development. The potential to address broader patient populations with KRAS (搜索)-mutant cancers could expand market opportunities and establish the company as a leader in precision oncology innovation.